TrialClinical pharmacokinetics2003

No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.

Troy C Sarich et al.PubMed ↗Publisher ↗

No numbers read from the abstract.